3 Bay Area Cal State schools to merge administrative services amid budget crunch
In addition to many cost-cutting measures the school had undertaken, 'we have also been looking for innovative ways to reduce expenses, particularly administration costs,' Mahoney went on to say.
Mahoney went on to put forth a 'new effort toward financial sustainability' that Cal State University Chancellor Mildred Garcia had announced at Tuesday's board of trustees meeting. Mahoney explained that she, along with the presidents of Cal State East Bay and Sonoma State University had provided Garcia with a written commitment to 'create a singular administrative network.'
Bay Area elementary schools make 2025 California Distinguished list
The network, she explained, would integrate finance and administrative services including budget, audit, capital planning design and construction, human resources, payroll, procurement, IT, and academic technology. It would be called the San Francisco Bay Region Network.
Additional services that could also be integrated under the network's umbrella include library services, Title IX/DHR operations, and some back-office financial aid, admissions, and records services. However, the universities would remain independent of one another, Mahoney maintained.
'Please be assured we are not proposing a merger of the three universities,' she said. 'Cal State East Bay, San Francisco State, and Sonoma State University will remain independently accredited universities.'
SFSU does not plan to implement layoffs as a result of the integration, Mahoney said.
'Existing employees in administration and finance functions will be needed as part of the networked operation, campus-based service centers, and during the design and transition period,' she said.
The proposed network, which Mahoney said is at the beginning stages, would not stave off any of the other budget reduction initiatives underway at the schools. Both SFSU and Sonoma State have recently announced sweeping cuts to their athletic programs, with Sonoma State doing away with theirs entirely.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Are Wall Street Analysts Predicting Danaher Stock Will Climb or Sink?
Science and technology company Danaher Corporation (DHR), headquartered in Washington, D.C., designs, manufactures, and markets innovative products and services in the fields of life sciences, diagnostics, and biotechnology. The company operates through three broad segments: Biotechnology, Life Sciences, and Diagnostics. With a market capitalization of $147.31 billion, Danaher's offerings are used in research labs, hospitals, and industrial settings to advance scientific discovery, improve patient care, and ensure water quality and food safety. Shares of this medical technology company have declined by 22.2% over the past 52 weeks, as the company experiences a slowdown in its performance. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For comparison, the broader S&P 500 Index ($SPX) has gained 19% over the same period. This year, Danaher's stock price has declined by 8.9% year-to-date (YTD), while the S&P 500 index has increased by almost 10%. Taking a closer look, Danaher's shares have also been underperforming the sector-specific Robo Global Healthcare Technology and Innovation ETF (HTEC), which has gained 5.2% over the past 52 weeks and 4.7% YTD. For the fiscal year 2024, Danaher's topline declined marginally year-over-year (YOY). While the company's weak price action has coincided with an annual topline slowdown, its recent quarterly financials came in better than expected, sparking a 4.2% surge in its share on Jul. 23. For the second quarter of fiscal 2025, its sales increased by 3.4% YOY to $5.94 billion, which was better than the $5.84 billion that Wall Street analysts were expecting. At the heart of this growth was the Danaher Business System, along with gains in its bioprocessing business. Along with its latest earnings reveal, Danaher also announced a notable executive shakeup, with a new CFO expected to take over next year and a new General Counsel already appointed. For the fiscal year 2025, ending in December 2025, Wall Street analysts expect a modest growth in Danaher's bottom line, forecasting a 3.9% YOY growth in its EPS to $7.77 on a diluted basis. The company has a mixed history of surpassing consensus estimates, topping them in three of the trailing four quarters and missing them on one occasion. Among the 23 analysts covering Danaher's stock, the consensus is a 'Strong Buy.' That's based on 19 'Strong Buy' ratings, one 'Moderate Buy' rating, and three 'Holds.' The configuration of the ratings appears slightly more bullish than two months ago, when the stock had 18 'Strong Buy' ratings. Highlighting confidence in the company's prospects amid current market conditions, Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Danaher's stock in late July and reiterated the $250 price target. Additionally, underscoring a positive outlook, Baird analyst Catherine Schulte reaffirmed the firm's 'Outperform' rating, while raising the price target on the stock from $226 to $229. Danaher's mean price target of $243.33 indicates a premium of 16.3% from the current market prices. The Street-high price target of $310 implies a potential upside of 48.2%. On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Miami Herald
04-08-2025
- Miami Herald
HBCU drops tennis programs in re-alignment
PRAIRIE VIEW, Texas - Prairie View A&M University (PVAMU), a leading HBCU located in Texas, has announced the immediate end of its Men's and Women's Tennis programs. The move is part of a larger plan to reshape Panther Athletics for long-term stability and a better student-athlete experience. This decision follows a full review of the university's athletic programs. With college sports changing quickly, PVAMU and many other HBCU athletic departments must make hard choices to remain competitive while staying true to their mission. By realigning its resources, the university aims to focus on sports that serve more student-athletes and better fit its long-term goals. Honoring a Proud Legacy While Planning Ahead For years, PVAMU's tennis teams have reflected the spirit of HBCU pride-on the court and in the classroom. Their success, commitment, and sportsmanship will always be part of the university's history. However, with rising costs and aging facilities, the university saw a need to invest more in its primary sports. University leaders believe this change will help improve athletic facilities, grow student services, and ensure future progress. PVAMU also plans to boost support for women's sports, helping the school meet Title IX requirements and open more doors for female athletes. Student-Athlete Support is a Top Priority PVAMU is working hard to support all tennis student-athletes during this transition. Scholarships will remain in place through graduation for those in good academic standing who choose to stay. Student-athletes who want to continue playing tennis elsewhere will receive help with transfers, academic planning, and personal support. The university will also provide mental health and wellness services to help students stay on track. While this marks the end of an era, PVAMU remains focused on building a strong, modern athletics program. The goal is to reflect the core values of HBCUs-excellence, access, and community. Panther Athletics will continue to grow in a way that supports student success on every level. The post HBCU drops tennis programs in re-alignment appeared first on HBCU Gameday. Copyright HBCU Gameday 2012-2025
Yahoo
04-08-2025
- Yahoo
Lilly's Push to $1 Trillion Derailed by Trade Risks and Obesity Drug Speedbumps
(Bloomberg) -- A year ago, Eli Lilly & Co. was poised to become the first pharmaceutical company to register a trillion-dollar market valuation. It still hasn't cracked that ceiling. Seeking Relief From Heat and Smog, Cities Follow the Wind Chicago Curbs Hiring, Travel to Tackle $1 Billion Budget Hole NYC Mayor Adams Gives Bally's Bronx Casino Plan a Second Chance Instead, a series of weak earnings reports, a setback for its obesity drug and threats of sky-high tariffs have taken Lilly investors on a wild ride only to deposit them almost exactly where they started. Down 21% from an August record, Lilly trades at $762 a share and is worth $722 billion — not bad, but not the lofty figures investors were expecting. 'There's a lot of investors who are pretty frustrated who may have paid $800 or $900 a share,' said Ken Mahoney, CEO at Mahoney Asset Management. 'There's a lot of people that are trapped in the stock and would like to see the stock go higher, obviously, but then again, they're asking for a lot.' Rewind 12 months and the ask didn't seem so monumental. The Indianapolis-based company was one of the hottest stocks on Wall Street, at one point becoming the 9th most valuable in the S&P 500 Index with a peak valuation of $912 billion. Lilly's obesity drug, known as Zepbound, was stealing market share from its biggest rival, Novo Nordisk A/S's Wegovy. The company also boasted a promising outlook for its GLP-1 medications. Since then, Lilly has underperformed the S&P 500 by about 23 percentage points. The ride started to get choppy last fall when the drugmaker posted a rare quarterly sales miss and trimmed its annual revenue forecast. It became more turbulent in the past eight months. Zepbound and the diabetes shot, Mounjaro, both missed estimates in two consecutive quarters, raising questions about management's ability to predict demand. 'Expectations went up,' Mahoney added. 'This is how it goes on Wall Street. You get a couple of good quarters and keep raising estimates or competition comes in because that's a great place to be and next thing you know, they're not hitting those numbers.' Then in May, drug benefit manager CVS Health Corp. dropped Zepbound from its list of preferred drugs and replaced it with Novo's Wegovy. The news sent Lilly shares plunging 12% for the worst drop since October 2008. Lilly had been expanding its market share until the change took effect, though the extent of any damage won't be clear until the firm reports third-quarter results in the fall. And then there's the pharmaceutical industry's special place in Donald Trump's trade wars. The president has threatened debilitating tariffs in an effort to force manufacturing back into the US. Last week, he demanded major suppliers drastically cut costs or face additional, unspecified penalties. The threats have taken the sheen off what was once a glittering industry. 'It's an unloved sector right now,' according to Rhys Williams, chief strategist at Wayve Capital Management LLC. Lilly has the chance, though, to resume its push toward $1 trillion valuation. The firm is expected to deliver data in the next couple months from two late-stage trials of an experimental oral GLP-1 pill called orforglipron to treat obesity. Zepbound may also get regulatory approval to treat other diseases such as for the heart and liver, expanding access to more patients. Good news for Zepbound came Friday, after a report that Medicaid and some Medicare drug plans will experiment with covering expensive weight-loss drugs. Lilly shares rose 3% on the news. Allen Bond, a portfolio manager for Jensen Investment Management, is betting its time to buy Lilly shares ahead of the data readout. 'The momentum is really good and they're really well positioned,' said Bond, who bought shares of the drugmaker for the first time in June. 'They have other very good drug franchises as well that aren't GLP-1s and they've got a really good track record of actually getting drugs into market.' The trial results leave orforglipron on the cusp of going commercial, according to BMO Capital Markets analyst Evan David Seigerman. He expects positive data would put the pill on track for regulatory approval in 2026. 'We expect Lilly shares could trade up 7-10% on positive data, pressuring Novo and Amgen,' said Seigerman. He put a target of $920 for the shares. The sagging share price puts extra meaning on Lilly's second-quarter earnings report, due Thursday. Expectations have moderated after Novo cut its sales growth forecast last week. Analysts expect Lilly to report a 30% jump in sales compared to the year prior, with Zepbound's growth at nearly 150%. The Mounjaro diabetes shot is forecast to deliver a 45% increase. The company is expected to report a 42% climb in adjusted earnings. 'Earnings are going to be strong because you've got just this huge momentum still from people adopting GLP-1,' said Jensen's Bond. 'We expect earnings momentum to continue, but that's probably kind of priced in at this point.' Some of the moderation owes to Novo's troubles that led the Danish drugmaker to replace its chief executive. Despite concerns Lilly may face similar travails, Wall Street remains largely bullish. All but eight of the 37 analysts tracked by Bloomberg rate it a buy, with a Street consensus for shares to hit $960 in the next 12 months, a 26% jump from current levels and implies a valuation of $910 billion — almost exactly where it peaked last August. Mahoney remains somewhat skeptical and is waiting to see two quarters of accelerating growth before turning bullish. 'Back-to-back quarters where the companies meet the estimates and then raise the guidance, then that'd be very attractive,' Mahoney said. 'That's our definition of how we enter stocks. After the earnings reports, make sure there's no grenade that goes off.' How Podcast-Obsessed Tech Investors Made a New Media Industry AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay Russia Builds a New Web Around Kremlin's Handpicked Super App Everyone Loves to Hate Wind Power. Scotland Found a Way to Make It Pay Off What's Really Behind Those Rosy GDP Numbers? ©2025 Bloomberg L.P. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
